Intensification with autologous transplantation in non-Hodgkin's lymphomas;Les intensifications thérapeutiques avec autogreffe dans les lymphomes non Hodgkiniens

Bulletin du Cancer

Volumn 88, Issue 9, 2001, Pages 877-887

  Bosly, A ^a   Gisselbrecht, C ^a  

^a UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

Author keywords

Autologous transplantation; Intensification; Non hodgkin's lymphoma

Indexed keywords

CD20 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB;

ADOPTIVE IMMUNOTHERAPY; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DOSE RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PROGNOSIS; REVIEW;

BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; LYMPHOMA, HIGH-GRADE; LYMPHOMA, LOW-GRADE; NEOPLASM, RESIDUAL; PATIENT SELECTION; RECURRENCE; REMISSION INDUCTION; TRANSPLANTATION, AUTOLOGOUS;

EID: 0034800235     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Blood and marrow transplantation activity in Europe 1997: Special report
2. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma
3. Dose: A criticial factor in cancer chemotherapy
4. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol
5. Randomized trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients
6. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. A randomized, controlled trial
7. High dose therapy and transplantation in non-Hodgkin's lymphoma
8. Report of an international workshop to standardise response criteria for non-Hodgkin's lymphomas
9. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma
10. High-dose therapy and stem cell transplantation in follicular lymphoma
11. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma
12. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: A risk model
13. The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma
14. Identification of prognostic groups in follicular lymphoma
15. Low-grade follicular lymphoma: Multivariate analysis of prognostic factors in 484 patients: A study of the Groupe d'étude des lymphomes de l'adulte
16. Prognosis of follicular lymphoma: A predictive model based on a retrospective analysis of 987 cases
17. A predictive model for aggressive non-Hodgkin's lymphoma
18. A multi-states regression analysis for competing events in follicular lymphoma patients included in the Gelf-86 trial
19. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma
20. Patterns of survival in patients with recurrent follicular lymphoma: A 20-year study from a single center
21. Survival after relapse of low-grade non-Hodgkin's lymphoma: Implications for marrow transplantation
22. High dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up
23. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma
24. Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma
25. Autologous stem-cell transplantation (ASCT) improves survival after progression for patients with a follicular lymphoma (Gelf 86 protocols)
26. The Cup trial: A randomized study analysing the efficacy of high dose therapy and purging in low-grade non-Hodgkin's lymphoma (NHL)
27. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients
28. Incidence of histological transformation in follicular lymphoma patients included in the prospective Gelf 86 protocol
29. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies
30. High-dose therapy with autologous haemaropoietic support in patients with transformed follicular lymphoma: A study of 27 patients from a single centre
31. High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission
32. Value of autologous bone marrow transplantation (ABMT) in 42 patients with follicular lymphomas responsive to conventional chemotherapy: A « France Autogreffe » study
33. Myeloablative radiochemotherapy followed by blood-stem cell-transplantation significantly prolongs the disease-free interval in patients with low-grade lymphomas as compared to standard maintenance with interferon alpha: Results of a prospective randomized comparison by the German low grade Lymphoma Study Group (GLSG)
34. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma
35. The clinical significance of molecular response in indolent follicular lymphomas
36. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy of follicular lymphoma patients with a low tumor burden: Clinical and molecular evolution
37. Immunological purging of marrow assessed by PCR before autologous bone marrow transplantation for B cell lymphoma
38. Autologous stem cell transplantation for non-hodgkin's lymphomas: The role of graft purging and radiotherapy post-transplantation. Results of a retrospective analysis on 120 patients autografted in a single institution
39. + peripheral blood stem cells: Retained engraftment capability and reduced tumour cell content
40. Bone marow transplantation prolongs survival after relapse in aggressive lymphoma patients treated with the LNH-84 regimen
41. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP
42. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
43. Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas
44. The VIM3-AraC regimen followed by autologous stem cell transplantation in refractory or relapsing aggressive non-Hodgkin's lymphoma: A prospective study of 71 consecutive cases
45. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicentre phase II study
46. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: Is there a chance for cure?
47. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma
48. Blood and marrow transplantation in relapsed or refractory non Hodgkin's lymphomas
49. Progress in the non-Hodgkin's lymphomas
50. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma
51. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytatabine in aggressive non-Hodgkin's lymphoma with partial response to frontline chemotherapy: A prospective randomized italian multicenter study
52. High-dose therapy and autologous bone marrow transplantation in partial remission after first line induction therapy for diffuse non-Hodgkin's lymphoma
53. Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma
54. High-dose therapy followed by stem cell transplantation in partial response after first-line induction therapy for aggressive non-Hodgkin's lymphoma
55. Residual mediastinal mass in malignant lymphoma: Value of magnetic resonance imaging and gallium scan
56. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy
57. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
58. Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle
59. The treatment of progressive non Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation
60. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: Very low treatment-related mortality in 100 patients in sensitive relapse
61. Evidence of graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation
62. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): Long-term follow-up and analysis of prognostic factors
63. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who are still responsive to conventional dose therapy
64. The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas
65. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide and cyclophosphamide and autologous bone marrow transplantation
66. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma
67. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the Spanish Cooperative Group GEL/TAMO
68. The role of intensive therapy and autologous blood and bone marrow transplantation for chemorherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: Identification of maior pronosric groups
69. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
70. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma
71. Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: A randomized study from the Gela: LNH RP93
72. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma: Results of a single-centre study of 65 patients
73. Ifosfamide, carboplatin and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
74. Autologous bone marrow transplantation versus chemotherapy in relapsed/refractory non-Hodgkin's lymphoma: Estimates of long-term survival from the recent literature
75. Autologous bone marrow transplantation as consolidation therapy for non-Hodgkin's lymphoma patients with poor prognostic features
76. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor risk aggressive lymphoma: A pilot study
77. Autologous bone marrow transplantation in poor risk high-grade non-Hodgkin's lymphoma in first complete remission
78. Long-term haematological reconstitution following BEAM and autologous transplantation of circulating progenitor cells in non-Hodgkin's lymphoma
79. Intensified and high dose chemotherapy with granulocyte colony stimulating factor and autologous stem cell transplantation support as first-line therapy in high-risk diffuse large cell lymphoma
80. Sequential high-dose therapy for high-risk intermediate and high-grade adult patients with non-Hodgkin's lymphoma. A pilot study of Goelams group
81. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group
82. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: A study of 464 patients. Groupe d'étude des lymphomes de l'adulte
83. Failure of first-line inductive high-dose chemotherapy (HDC) in poor-risk patients (pts) with aggressive lymphoma: Updated results of the randomized LNH93-3 study
84. High-dose chemotherapy with autologous stem cell transplantation in high grade NHL: First analysis of a randomized study
85. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma
86. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2
87. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol. A « Groupe d'Étude des Lymphomes de l'Adulte » study
88. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas. Report of the study
89. High-dose therapy for diffuse large-cell lymphoma in first remission. Review
90. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: Value of augmented preparative regimens. A Southwest Oncology Group trial
91. Allogeneic bone marrow transplantation for lymphoma
92. Allogeneic transplantation for lymphoma produces a lower relapse rate than autologous transplantation but survival is worse because of higher treatment related mortality: A report of 764 cases from the EBMT lymphoma registry
93. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): A series of 73 patients from the SFGM database. Société française de gteffe de moelle
94. Evidence of graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation
95. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma
96. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation
97. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-control analysis of the European Bone Marrow Transplant Group registry data
98. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma
99. Management of lymphoma recurrence after allogeneic transplantation: The relevance of graft-versus-lymphoma effect
100. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone marrow transplantation
101. T cell-depleted allogeneic bone marrow transplantation for high-risk non Hodgkin's lymphoma: Clinical and molecular follow-up
102. Allogeneic transplantation for low-grade lymphoma: Long-term follow-up
103. Graft-versus-lymphoma effect of donor leucocyte infusion shown by real-time quantitative PCR analysis of t(14;18)
104. Allogeneic peripheral stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma
105. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
106. Immunotherapy with recombinant human interleukin-2 (rIL-2) and recombinant alpha interferon in lymphoma patients post-autologous marrow or stem cell transplantation
107. Interferon as maintenance therapy in refractory malignant lymphoma
108. Interferon alpha 2b versus no treatment after intensive therapy and autologous stem cell transplantation for relapsing lymphoma: Preliminary results of an international randomized study on 174 patients